Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Stock Information for Monopar Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.